论文部分内容阅读
肿瘤过继性细胞免疫治疗(adoptive cellular immunothera-py,ACI)是指转输具有抗瘤活性的效应细胞治疗肿瘤。目前ACI已逐步发展成为一类重要的肿瘤生物治疗方法。根据诱导方法和来源的不同效应细胞常包括如下几种:肿瘤浸润淋巴细胞(tumour infiltrating lymphocyte,TIL)、淋巴因子诱导的杀伤细胞(lymphokine-activated killer cells,LAK)、抗CD_3~+单克隆抗体激活的肿瘤杀伤细胞(anti-CD_3~+ monoclonalantibody activated killer cells,CD_3 AK)、细胞因子诱导的杀伤细
Adoptive cellular immunothera-py (ACI) refers to the delivery of effector cells with antitumor activity to treat tumors. At present, ACI has gradually developed into a class of important tumor biological treatment methods. Depending on the method of induction and the different sources of effector cells often include the following: tumor infiltrating lymphocytes (TIL), lymphokine-activated killer cells (LAK), anti-CD3 ~ + monoclonal antibody Activated anti-CD3 + monoclonalantibody activated killer cells (CD3 AK), cytokine-induced killer